Green A R, Johnson P, Mountford J A, Nimgaonkar V L
Br J Pharmacol. 1985 Feb;84(2):337-46. doi: 10.1111/j.1476-5381.1985.tb12918.x.
The effects in mice of administration of the anticonvulsants, progabide, sodium valproate, diazepam, carbamazepine and phenytoin on 5-hydroxytryptophan (5-HTP)-induced head-twitch, apomorphine-induced locomotion, clonidine-induced sedation, and beta-adrenoceptor and 5-HT2 receptor number have been examined. Repeated progabide administration (400 mg kg-1, i.p. twice daily for 14 days) enhanced the head-twitch response the effect lasting for over 8 days after the last dose, and also increased 5-HT2 receptor number in frontal cortex. Progabide (400 mg kg-1, i.p.) enhanced the head-twitch response when given once daily for 10 days and when given intermittently (5 times over 10 days) but not after 1 day of administration. Repeated Na valproate (400 mg kg-1, i.p.) also increased the 5-HTP-induced head-twitch response and 5-HT2 receptor number in the frontal cortex when given twice daily for 14 days, but no behavioural enhancement was seen after 10 days' treatment. Diazepam (1.25 mg kg-1, i.p.) twice daily for 14 days increased the head-twitch response and 5-HT2 receptor number. Repeated progabide and valproate (but not diazepam) administration attenuated the sedation response to the alpha 2-adrenoceptor agonist, clonidine (0.15 mg kg-1) but neither drug altered beta-adrenoceptor number in the cerebral cortex. No changes in apomorphine-induced locomotor behaviour were seen after progabide, valproate or diazepam. Repeated carbamazepine (20 mg kg-1) or phenytoin (40 mg kg-1) administration failed to alter any of the biochemical or behavioural parameters listed above. Like repeated electroconvulsive shock (ECS), progabide altered the head-twitch response, clonidine-induced sedation response and 5-HT2 receptor number. Unlike repeated ECS, it did not alter beta-adrenoceptor number or the apomorphine-induced locomotor response. These data suggest that ECS may produce some changes in monoamine function by altering GABA metabolism as has previously been postulated.
已研究了抗惊厥药普罗加比、丙戊酸钠、地西泮、卡马西平和苯妥英对小鼠5-羟色氨酸(5-HTP)诱导的头部抽搐、阿扑吗啡诱导的运动、可乐定诱导的镇静以及β-肾上腺素能受体和5-HT2受体数量的影响。重复给予普罗加比(400mg/kg,腹腔注射,每日两次,共14天)可增强头部抽搐反应,该效应在最后一剂后持续超过8天,并且还增加了额叶皮质中的5-HT2受体数量。普罗加比(400mg/kg,腹腔注射)连续10天每日给药一次以及间歇给药(10天内给药5次)时可增强头部抽搐反应,但给药1天后则无此作用。重复给予丙戊酸钠(400mg/kg,腹腔注射)连续14天每日两次时,也可增加5-HTP诱导的头部抽搐反应以及额叶皮质中的5-HT2受体数量,但治疗10天后未观察到行为增强。地西泮(1.25mg/kg,腹腔注射)连续14天每日两次可增加头部抽搐反应和5-HT2受体数量。重复给予普罗加比和丙戊酸钠(但不包括地西泮)可减弱对α2-肾上腺素能受体激动剂可乐定(0.15mg/kg)的镇静反应,但两种药物均未改变大脑皮质中的β-肾上腺素能受体数量。给予普罗加比、丙戊酸钠或地西泮后,阿扑吗啡诱导的运动行为未见变化。重复给予卡马西平(20mg/kg)或苯妥英(40mg/kg)未能改变上述任何生化或行为参数。与重复电惊厥休克(ECS)一样,普罗加比改变了头部抽搐反应、可乐定诱导的镇静反应和5-HT2受体数量。与重复ECS不同的是,它未改变β-肾上腺素能受体数量或阿扑吗啡诱导的运动反应。这些数据表明,ECS可能如先前推测的那样通过改变GABA代谢而在单胺功能上产生一些变化。